Introduction
Clinical research is one of the fundamental features of evidence based medicine. The highest level of evidence in clinical research is generated by aggregated evidence of randomized controlled trials (RCTs; Guyatt et al., 2000) . Pooling the data of trials involves careful and meticulous analysis of the internal validity of the included trials in order to know if the research question has been answered correctly and is free from bias (Higgins and Green, 2011) . Bias in clinical trials may be described as systematic errors that favour one outcome over the other. Implementation of biased trial results leads to the use of ineffective drugs and devices, resulting in poor patient care and waste of money (Gluud, 2006) . Potential sources of bias may be classified into selection bias (the selection and randomization of patients), performance bias (blinding of participants and personnel), detection bias (blinding of outcome assessment), attrition bias (incomplete outcome data caused by withdrawals) and reporting bias, caused by selective outcome reporting (Higgins and Green, 2011) .
Selective outcome reporting occurs if some outcomes are reported while others are not, which threatens the validity of trials, by increasing the likelihood that the results were caused by chance, and potentially renders published results misleading (Higgins and Green, 2011; Dwan et al., 2013) . Selective outcome reporting is mainly determined by the choice of the primary outcome measure (Chan et al., 2004) . There are two types of selective outcome reporting. The first is that the primary outcome measure is a surrogate outcome measure that is not the most relevant for answering the research question; the second is that there are inconsistencies between planned and reported primary outcome measures (Grimes and Schulz, 2005; Lassere, 2008) .
Selective outcome reporting is particularly relevant to reproductive medicine, especially IVF and ICSI, since there is a wide range of possible primary outcome measures to choose from. Outcome measures can vary from number of oocytes retrieved and hormone levels to singleton live birth and birth emphasizing a successful singleton at term (Braakhekke et al., 2014a,b) . In trials aiming to assess differential effectiveness, the number of oocytes retrieved for instance, represents an obvious surrogate outcome that may reach significance, whereas live birth rate does not.
Selective outcome reporting overlaps with publication bias, i.e. bias that arises when studies are published or not, depending on their results. One of the drivers behind publication bias is that studies that report positive or significant results are more likely to be published and this, in turn, may lead to selective outcome reporting of the significant outcomes in favour of the non-significant ones (Dwan et al., 2013) .
Selective outcome reporting may be related to sponsorship, since sponsorship by industry is known to negatively influence valid interpretation of trial results by more often reporting on outcomes favourable to the sponsor's products (Vandenbroucke et al., 2000; Lundh et al., 2012; Flacco et al., 2015) . It is, at present, unknown whether RCTs on IVF and ICSI are subject to selective outcome reporting and whether this is related to sponsorship. The aim of this study was therefore to evaluate this by performing a systematic review of RCTs in couples undergoing IVF and ICSI.
Materials and Methods

Literature search
A medical information specialist (JL) performed a systematic search in OVID MEDLINE, OVID EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL) and the publisher subset of PubMed to identify RCTs on IVF and/or ICSI in humans. The search strategy consisted of MeSH terms and text words for the concepts IVF and ICSI combined with a methodological search filter for RCTs that was adapted from the Cochrane MEDLINE RCT-filter (Glanville et al., 2006) . We included human RCTs, published in English, that compared (cost) effectiveness of interventions in IVF and ICSI and were published between January 2009 until March 2016. At first, we chose a five-year interval from 2009 to 2014, that we updated before preparing this manuscript. The reason to choose a recent time period is that trial registries and guidelines on trial reporting have become essential developments in the last decade. We excluded duplicates and trials with study designs other than RCTs. We excluded studies if the subject was not IVF or ICSI, if the record was only an abstract submitted for a conference without a published RCT, if the study turned out not to be a RCT, if pregnancy was not an outcome, if it was not written in English and if we could not retrieve the full text.
Data extraction
Two researchers (MB and IS) independently extracted the data from trials published between January 2009 and March 2016. First, we extracted some general characteristics of the included trials: journal category (high impact factor versus medium to low impact factor with a cut-off level of 3.5), sample size (categorical) and power calculation (yes or no). For the analysis of sample sizes, we included trials that randomized women, and excluded trials that randomized oocytes or embryos.
Second, we classified the primary outcome measures as clinical or surrogate outcome measures. We defined a clinical outcome as 'an outcome of major clinical importance', i.e. clinical/ongoing pregnancy or live birth and a surrogate outcome as an outcome measure that 'substitutes for a clinical event of true importance', e.g. biochemical pregnancy or number of oocytes retrieved (Grimes et al., 2010) . We consulted trial registries to rule out a discrepancy between planned and reported primary outcome measures. The trial registries we consulted were clinicaltrials.gov, ISRCTN, NTR, IRCT, KHUCTR, Eudra, DRKS and ChiCTR.
Third, because of the overlap between selective outcome reporting and publication bias, we categorized the results of the trials in 'positive' and 'negative'. We defined positive results as those that were statistically significant in favour of the tested intervention, negative results as those that were statistically significant in favour of the standard intervention and nonsignificant results as those where no evidence of a difference was found between the interventions.
Fourth, we recorded the presence of sponsorship statements. If information on sponsorship was provided, the trials were categorized into commercial sponsorship, public sponsorship and no sponsorship. We defined commercial sponsorship as sponsorship by pharmaceutical companies and companies that develop medical devices, and public sponsorship as sponsorship by the government or medical research councils and charities. Trials were categorized as being not sponsored if this was explicitly stated.
Statistical analysis
We described the general characteristics of the trials, the presence or absence of sponsorship and the direction of the trial results as counts and percentages. We calculated odds ratios and confidence intervals using IBM ® SPSS ® Statistics version 23, to test differences between the studied trial characteristics related to the sponsorship of the trial. To test if direction of the trial results was related to the sponsorship of the trial, we used the Pearson-Chi-square test, IBM ® SPSS ® Statistics version 23.
Since the majority of the papers were secondarily excluded because of the non-reporting of sponsorship, we added an secondary analysis. We ran our analysis again, comparing the trials that did not report sponsorship with the trials that did report sponsorship. We also ran a scenario analysis in which we presumed that the trials not reporting sponsorship were publicly sponsored.
Results
Our search identified 1879 records. The flowchart is shown in Fig. 1 . After screening on subject, study design, language and duplicates in title and abstract, we selected 541 articles for full text reading, of which we excluded 126 articles because of various reasons specified in the flowchart. We included 415 articles in our database of which 72 trials (17%) reported commercial sponsorship, 79 trials (19%) reported public sponsorship, 29 trials (7%) reported no sponsorship and 235 trials (57%) did not report on sponsorship. The 235 trials that did not report on sponsorship trials were excluded from further analysis.
The characteristics of the included trials are summarized in Table I . Commercially sponsored trials were significantly more often published in high impact factor journals compared to trials with public or no sponsorship. Commercially sponsored trials significantly more often had a sample size of over 500 participants compared to trials with public sponsorship. Power calculations were significantly more often performed in commercially sponsored trials compared to trials with public or no sponsorship.
Data on primary outcome measures are summarized in Table II . The majority of the trials had a surrogate outcome as the primary outcome measure. There was no evidence of a difference between commercially, public and not sponsored trials.
Data on discrepancies between registered and reported primary outcome measures are summarized in Table III . Commercially sponsored trials were significantly more often registered in a trial registry compared to trials with public or no sponsorship. Of the 114 registered trials, 21 trials (18%) provided different primary outcomes in their manuscript compared to the registry. Of these 21 trials, 12 registered a clinical primary outcome while a surrogate primary outcome was reported in the manuscript. The other nine trials registered a surrogate primary outcome, while a clinical primary outcome was reported in the manuscript. There was no difference between commercially, public and not sponsored trials.
Data on direction of trial results are summarized in Table IV . A minority of the trials reported negative results which were statistically significant in favour of the standard intervention. There was no association between the direction of trial results and sponsorship.
The additional analyses are summarized in Supplementary Tables S1-IV. Trials that did not report on sponsorship were significantly less often published in journals with a high impact factor and significantly less often performed power calculations compared to trials that did report on sponsorship. Also, the trials that did not report on sponsorship were significantly less often registered in a trial registry. We found no other differences between trials that did not report on sponsorship and trials that did report on sponsorship. When presuming that all trials that did not report sponsorship were publicly sponsored, we found no outcomes that differed from our primary analysis
Discussion
The majority of the analysed trials in this systematic review reported on surrogate primary outcome measures, while a considerable proportion reported primary outcomes different from that listed in the trial registry and some trials did not mention a primary outcome measure at all. A minority of the trials reported on negative results. We did not find an association between selective outcome reporting and sponsorship. We did find differences between some general characteristics of the trials, related to sponsorship. The trials that reported commercial sponsorship were more often published in high impact factor journals, more often had large sample sizes, more often performed power calculations and were more often registered in trial registries compared to trials with public or no sponsorship. Our study has certain limitations. We restricted our sample to English-language RCTs and did not include cohort and case-control studies, while selective outcome reporting might also play a role in trials with these study designs. In our study, we focused on reporting bias only, although selection bias, performance bias, detection bias and attrition bias might also be influenced by sponsorship. Because of our small dataset, we made no geographic stratification, although there might be differences in the general regulations for the registration of trials. The majority of the trials did not report on sponsorship and we excluded these trials, which created a risk on sampling bias and a smaller sample size of trials with useful information. Our analysis might therefore be underpowered. However in our additional scenario analysis, we presumed that all trials that did not report on sponsorship were publicly sponsored. We think this is a more realistic scenario than the other option of all such trials being commercially sponsored, since in our primary analysis the majority of the trials were publicly sponsored. Furthermore, we did not found any striking differences after running the additional analysis.
From 2009 to thepresent, less than half of the published RCTs on IVF and ICSI reported sponsorship. This is not in line with the CONSORT statement . We did find a positive trend in the reporting of sponsorship, from 26% in 2009 to 49% in 2015. To be able to perform high quality analyses on this topic in the future, we feel that all submitted manuscripts should report on sponsorship and that this should be taken into account in the peer review process. We considered contacting the authors of the manuscripts that did not report on sponsorship, but we rejected this idea for two reasons. First, we wanted to report on published data and not on unpublished data and second, we felt that, asking the authors for a statement on sponsorship would not necessarily result in a trustworthy insight in sponsorship, or in other words, in asymmetrical data, which would be unfortunate, especially on this topic.
The fact that only 79 of 180 trials (44%) report public sponsorship is an issue that needs attention. The trials we selected were designed to improve clinical outcome in couples with subfertility and therefore have the potential to guide towards better clinical decision making. If reproductive health is seen as an important collective heath issue, this low public contribution is worrisome.
Our analysis of the trials that did report on sponsorship showed that commercially sponsored trials are more often published in journals with a high impact factor. This is not surprising, since they report on larger sample sizes and more often perform sample size calculations that result in better underpinned conclusions of greater impact. Next to the origin of the sponsorship, these differences may also be due to the study budget, but information on budget of the studies was not available.
Still, conclusions from all evaluated trials, regardless of sponsorship, were mainly based on surrogate primary outcome measures, which is worrisome since clinical decisions cannot be made based on trials that report on surrogate primary outcome measures. Surrogate outcome measures can be of interest to explain the main results of a clinical trial and thereby provide insight into the underlying biological mechanisms. However the most relevant primary outcome measure for clinical trials in reproductive medicine, in our opinion, is ongoing pregnancy (Braakhekke et al., 2014a,b) . Discrepancies between the registered and reported primary outcome measure such as that found in our analysis, count for selective outcome reporting for two reasons. As primary outcomes are used for calculation of the sample size, this mechanism is no longer functional if predefined outcomes are subsequently changed (Chan et al., 2004) . Also, pre-defining primary outcome measures is necessary to prevent the researchers from cherry picking significant results and presenting these as the main findings of the study (Andrade, 2015) . Secondary findings may be of relevance and it is not wrong to report these findings and to discuss them, if only it is clearly stated that these findings are secondary, thus they do not correspond to the original power calculation and should be considered as hypothesis generating rather than for rejecting the null hypothesis. Discrepancies between the registered and reported primary outcome measure such as we found leads to false, or at least misleading, trial results.
A recent review has revealed similar discrepancies. The review included studies which compared published trial outcomes to trial outcomes documented in a publicly accessible clinical trials registry. The proportion of trials with an identified discrepancy between the registered and published primary outcome was 31% (Jones et al., 2015) .
In our analysis, only 11 trials (6%) reported negative results. This is possibly caused by publication bias, i.e. non-publication due to lack of submission or rejection of study reports, but can also be a part of selective outcome reporting (Dwan et al., 2013) . Commercially sponsored trials are especially at risk for publication bias since the company that owns the research data can decide to publish the data or not. The only way to differentiate between publication bias and selective outcome reporting is to get access to the raw research data. However, participant-level data from health related studies are rarely made available to external researchers (Alsheikh-Ali et al., 2011) .
In conclusion, we found inconsistencies in the choice and reporting of primary outcome measures, indicating selective outcome reporting in IVF and ICSI trials. We did not find an association between the existence of selective outcome reporting and sponsorship. Recently the COMPare team has monitored all trials published in the top five medical journals. This team analyses each trial for outcome switching, by comparing the protocol with the trial report. 
